ACAD
35.83
-0.9
-2.45%
AEMD
0.98
0.00
0.00%
APRI
1.82
-0.08
-4.21%
ARNA
27.31
-0.25
-0.91%
ATEC
4.12
-0.01
-0.24%
CNAT
5.01
-0.14
-2.72%
CRXM
0.103
-0.034
-24.8758%
CYTX
0.465
-0.021
-4.321%
DXCM
44.98
+0.03
+0.07%
GNMK
7.84
-0.22
-2.73%
HALO
17.77
+0.05
+0.28%
ILMN
205.18
-0.44
-0.21%
INNV
0.087
-0.003
-3.010%
INO
6.25
-0.07
-1.11%
ISCO
1.54
+0.03
+1.99%
ISIS
57.56
0.00
0.00%
LGND
143.35
-0.81
-0.56%
LPTN
2.93
-2.93
-100.00%
MBVX
0.74
+0.025
+3.4685%
MEIP
2.62
+0.14
+5.65%
MNOV
6.19
-0.19
-2.98%
MRTX
15.55
+1.2
+8.36%
MSTX
0.13
-0.01
0.00%
NBIX
58.96
-0.46
-0.77%
NUVA
54.57
+0.39
+0.72%
ONCS
1.29
+0.01
+0.78%
ONVO
1.4
-0.08
-5.41%
OREX
1.82
-0.05
-2.67%
OTIC
3.475
+0.025
+0.725%
QDEL
41.95
+0.24
+0.58%
RCPT
231.96
0.00
0.00%
RGLS
1.25
-0.07
-5.30%
RMD
78.79
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.24
0.00
-0.13%
SRNE
2.5
-0.1
-3.85%
TROV
0.809
-0.059
-6.7742%
VICL
2.38
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
39.65
+0.65
+1.67%
ACAD
35.83
-0.9
-2.45%
AEMD
0.98
0.00
0.00%
APRI
1.82
-0.08
-4.21%
ARNA
27.31
-0.25
-0.91%
ATEC
4.12
-0.01
-0.24%
CNAT
5.01
-0.14
-2.72%
CRXM
0.103
-0.034
-24.8758%
CYTX
0.465
-0.021
-4.321%
DXCM
44.98
+0.03
+0.07%
GNMK
7.84
-0.22
-2.73%
HALO
17.77
+0.05
+0.28%
ILMN
205.18
-0.44
-0.21%
INNV
0.087
-0.003
-3.010%
INO
6.25
-0.07
-1.11%
ISCO
1.54
+0.03
+1.99%
ISIS
57.56
0.00
0.00%
LGND
143.35
-0.81
-0.56%
LPTN
2.93
-2.93
-100.00%
MBVX
0.74
+0.025
+3.4685%
MEIP
2.62
+0.14
+5.65%
MNOV
6.19
-0.19
-2.98%
MRTX
15.55
+1.2
+8.36%
MSTX
0.13
-0.01
0.00%
NBIX
58.96
-0.46
-0.77%
NUVA
54.57
+0.39
+0.72%
ONCS
1.29
+0.01
+0.78%
ONVO
1.4
-0.08
-5.41%
OREX
1.82
-0.05
-2.67%
OTIC
3.475
+0.025
+0.725%
QDEL
41.95
+0.24
+0.58%
RCPT
231.96
0.00
0.00%
RGLS
1.25
-0.07
-5.30%
RMD
78.79
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.24
0.00
-0.13%
SRNE
2.5
-0.1
-3.85%
TROV
0.809
-0.059
-6.7742%
VICL
2.38
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
39.65
+0.65
+1.67%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.

Be Sociable, Share!